Publication
IQVIA APAC Insight Issue 8
The Future of Pharma-Private Insurance Collaborations in Asia Pacific

This issue of APAC Insight delves into the commercial and clinical development trends in Asia Pacific. It specifically examines these trends in China and India, respectively, which have a combined population of 2.7 billion people – 36 percent of the world’s population. For China, companies face new realities in obtaining reimbursement listings for their products. Providing evidence of value and re-evaluating pricing and access strategies will be essential to navigating this new environment.

In India, passage of regulatory reform is raising hopes that 2018 will see a resurgence in clinical trials in the country after years of uncertainty. Despite having positive attributes for clinical research, including a large population of treatment-naïve patients, India’s regulatory complexity and uncertainty has kept companies away. That may be changing.

We also look at how collaborations between biopharma companies and private insurers can close the affordability gap in the region, which is preventing high-cost/high-value innovative products from reaching patients in need.

Finally we examine the use of artificial intelligence (AI) and large data sets in order to improve outcomes for cancer patients and help deliver greater value in cancer care.

 

Contact Us